The Role of Lebrikizumab in the Treatment of Atopic Dermatitis in the Adult Population
Division
West Florida
Hospital
Largo Medical Center
Document Type
Manuscript
Publication Date
7-4-2023
Keywords
IL-13, atopic dermatitis, biologics, eczema, immunosuppressants, management
Disciplines
Dermatology | Skin and Connective Tissue Diseases
Abstract
Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD. In a phase III trial, 74% of adults with AD treated with lebrikizumab 250 mg every 4 weeks achieved an Investigator Global Assessment of 0/1, 79% achieved Eczema Area and Severity Index 75 and 79% experienced improvements in pruritus numeric rating scale scores relative to placebo. Common adverse effects in the ADvocate1 and ADvocate2 trials were conjunctivitis (7 and 8%, respectively), nasopharyngitis (4 and 5%, respectively) and headache (3 and 5%, respectively). Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management.
Publisher or Conference
Immunotherapy
Recommended Citation
Prajapati S, Fardos M, Desai AD, Feldman SR. The role of lebrikizumab in the treatment of atopic dermatitis in the adult population [published online ahead of print, 2023 Jul 4]. Immunotherapy. 2023;10.2217/imt-2023-0066. doi:10.2217/imt-2023-0066
